Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer.
A Oliver SartorPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castration-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA posttreatment can rapidly predict both time to progression and survival. See related article by Tolmeijer et al., p. xxx.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- prostate cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- small cell lung cancer
- peritoneal dialysis
- prognostic factors
- radical prostatectomy
- electronic health record
- machine learning
- deep learning
- patient reported outcomes
- data analysis
- patient reported